🔬AI Startup Raises $215M to Automate Drug Discovery Labs
This could shake up the biotech supply chain
TL;DR
A new AI startup has raised $215M to automate drug discovery labs, aiming to accelerate research and insulate from geopolitical risks. Robots will perform 24/7 lab tasks, potentially reshaping biotech outsourcing.
A new AI startup has raised $215 million to automate drug discovery labs, aiming to accelerate research and insulate from geopolitical risks. Biotech companies traditionally outsource labor-intensive work to contractors in China, but this startup aims to reshore this work. The robots will perform 24/7 lab tasks, potentially reshaping the biotech supply chain. If you're in drug development, this could mean faster, more reliable lab work without relying on offshore contractors. The startup's human chemists will train robots to perform various lab tasks, and the robots will wear cameras and sensor gloves to ensure precision. With a valuation of $865 million, this startup is a major player in the AI-driven drug discovery space.
Key Points
Startup raised $215 million in funding, led by Lightspeed, with IVP, Premji Invest, and Lux Capital also participating.
The company's valuation is $865 million, positioning it as a major player in AI-driven drug discovery.
Biotech companies traditionally outsource labor-intensive work to contractors in China, but this startup aims to reshore this work.
Robots will perform 24/7 lab tasks, potentially reshaping the biotech supply chain and accelerating drug discovery.
Human chemists will train robots to perform various lab tasks, with robots wearing cameras and sensor gloves for precision.
Why It Matters
If you're in drug development, this could mean faster, more reliable lab work without relying on offshore contractors. The startup's human chemists will train robots to perform various lab tasks, and the robots will wear cameras and sensor gloves to ensure precision. With a valuation of $865 million, this startup is a major player in the AI-driven drug discovery space.
Comments
Be the first to comment
Enjoyed this article?
Get it daily. 7am. Free. Reads in 5 minutes.